Drug Profile

OBI 998

Alternative Names: OBI-998

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OBI Pharma
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 May 2023 No recent reports of development identified for preclinical development in Cancer in Taiwan (Parenteral)
10 Apr 2021 Pharmacodynamic and pharmacokinetic data from a pre-clinical trial in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
28 Jan 2020 OBI Pharma has patent protection for OBI 998 (OBI Pharma website - January 2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com